Page 1
`PTO/SB/08 (09-06)
`
`
`Approved for use through 03/31/2007. 0MB 0651-0031
`
`
`
`
`U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
`
`
`
`
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB
`
`
`
`control number
`
`�
`
`Substitute for form 1449/PTO
`
`Complete if Known
`
`Number 13/875,252
`Aoolication
`Mav 1, 2013
`
`Filini:i Date
`First Named Inventor Adrian S. Rav
`Art Unit
`1629
`Examiner Name
`Zenab 0. Olabowale
`(use as many sheets as necessary)
`I 1
`.._Sheet
`Attorney Docket Number 37 JD-197097-US
`
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`
`Date Submitted: August 31, 2015
`
`I of I 1
`
`�
`
`....
`
`Exami
`! --------�----l
`Cite e-
`ner
`Initials
`Code2 (if
`known)
`
`Publication Date
`
`MM-DD-YYYY
`
`Pages, Columns, Lines,
`
`Where Relevant
`Name of Patentee or Applicant of
`
`
`Cited Document
`Passages or Relevant
`
`Fiaures Aooear
`
`I Document Number
`No.1 I Number-Kind
`
`U.S. PATENT DOCUMENTS
`
`..
`... ---·-
`- ·. ·--··
`
`----·-
`
`
`
`·-·----··-----.
`
`
`
`. ·----·---·····--··-··- ·-·�-�
`
`
`
`UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS
`
`
`
`I U.S. Patent Application Filing
`Pages, Columns, Lines,
`Exami
`Date of
`Where Relevant
`
`
`of Cited Document Name of Patentee or Applicant
`Cite L
`Document
`ner
`
`
`No.1 I Serial Number-Kind Code,-
`I
`Initials
`Passages or Relevant
`Cited Document
`MM-DD-YYYY
`Fiqures Appear
`(if known)
`
`ner
`
`Exami I
`FOREIGN PATENT DOCUMENTS
`Cite Foreiqn Patent Document Publication Date
`
`
`�nitials I
`No.1 Country Code"Number'' MM-DD-YYYY
`Kind Code5
`(if known)
`
`Pages, Columns, Lines,
`
`Name of Patentee or
`
`Where Relevant
`
`Applicant of Cited Documents Passages
`
`Fiaures Aooear
`
`or Relevant r6
`
`i
`
`
`NON PATENT LITERATURE DOCUMENTS
`Exami
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate),
`title of the I
`r6
`ner Cite
`
`
`
`
`
`
`number(s), volume-issue etc.) date, page(s), serial, symposium, catalog, s No.1 item (book, magazine, journal,
`Initial
`I
`*
`
`publisher, city and/or country where published.
`
`
`
`
`Examination Report issued in Egyptian Application No. PCT 392/2014 dated July 1, 2015 (with English translation), 7 pages.
`
`I
`
`I i
`
`I
`
`I
`..
`
`Date
`Examiner
`I
`Considered 12/14/2015
`Signature !Zenab
`Olabowale/
`
`
`
`*EXAMINER: Initial 11 reference considered, whether or not c1tat1on 1s 1n conformance with MPEP 609. Draw line through c1tat1on 1f not 1n conformance and not
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of
`
`
`
`
`
`
`
`
`
`
`
`
`USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For
`Japanese
`
`
`
`
`
`
`
`patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by
`
`
`
`
`
`
`
`
`the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language
`
`Translation is attached.
`
`
`
`
`
`
`
`
`
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`
`
`
`
`
`
`
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hOurs to complete, including
`
`
`
`
`
`gathering, preparing, and submitting the completed application form to the US PTO. Time will vary depending
`
`
`upon the individual case. Any comments on the amount
`
`
`
`
`
`
`
`of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark
`
`
`
`
`P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents,
`Office,
`
`P.O. Box 1450, Alexandria, VA 22313-1450.
`
`Gilead 2001
`
`
`
`
`
`
`
`
`
`
`
`It you need assistance m completing the to,m, call 1-800..fJI 0-9199 (1-800-/86-9199) and select option 2.
`
`I-MAK V. Gilead
`
`IPR2018-00211
`ALL REFERENCES CONSIDERED EXCEPT WHERE UNED THROUGH.
`IZ.O.i
`
`
`
`
`
`
`
`

`

`Page 2
`
`PTO/SB/08 (0906)
`Approved for use through 03/31/2007. OMB 06510031
`US. Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB
`control number.
`
`Substitute for form 1449/PTO
`Complete if Known
`
`
`
`
`
`
`
`Application Number
`13/875,252
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`Filin Date
`May 1, 2013
`
`
`
`
`
`First Named Inventor
`Adrian 8. Ray
`.
`D t
`:
`
`
`
`
`Art Unit
`1629
`a e Submitted October 14, 2015
`
`Examiner Name
`OLABOWALE, ZENAB O.
`
`
`use as many sheets as necessary)
`
`Attorne Docket Number
`37JD-197097«US
`
`
`
`U.S. PATENT DOCUMENTS
`
`Document Number
`Cite [e.....w Publication Date
`No.1 i
`Number—Kind Code (if
`MM-YYYY
`r
`k
`nown)
`___________________________________439111118129w“..._-_W..-._._i__QZ_-_29.11wm-_w Cana‘es at 3'-
`
`_
`1272011
`____________ 2011/306541 “
`8—2013
`8513298
`
`Name of Patentee or Applicant of
`Cited Document
`
`Pages, Columns, Lines.
`Where Relevant
`Passages or Relevant
`.
`Figures Appear
`
`Canales et ai.
`
`
`
`‘
`Erxamin
`.
`.
`_,
`initials
`
`
`
`
`
`
`
`
`
`FOREIGN PATENT DpCUMENTS
`‘
`.
`Publication Date
`MM-DD—YYYY
`
`Name of Patentee or
`Applicant of Cited Documents
`
`Pages. Columns, Lines,
`Where Relevant
`Passages or Relevant
`Fiures Auear
`
`_
`Examiner
`Initials*
`
`.
`Cite ;
`No.1
`‘
`
`.
`Foreign Patengpocqmegt .
`COL/0W 00d? Number
`Kind Code
`‘
`
`,
`E
`Iggy“
`
`Cite i
`N01 i
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`item (book, magazine, journal, serial. symposium, catalog, etc.) date, page(s), volume—issue number( ),
`publisher, city and/or country where published.
`
`Lok, et ai., "Combination Therapy with EMS-790052 and EMS—650032 Alone or with Pegyiated
`interferon and Ribavirin (peglFN/RBV) Results in Undetectable HCV RNA Through 12 Weeks of
`Therapy in HCV Genotype 1 Null Responders”, AASLD, The Liver Meeting in Boston, MA, October 29-
`November 2, 2010, poster.
`'
`Office Action issued in Eurasian Application No. 201490588 dated August 3, 2015 (with English
`translation), 4 pages.
`* Office Action issued in Mexican Application No. MX/a/2014/003145 dated July 23, 2015 (with English
`translation), 14 pages.
`
`Sharp, “BMS—790052/BMS-650032 Combo Cures Hepatitis C without Interferon", HIV and
`Hepatitiscom Coverage of the 46lh Annual Meeting of the European Association for the Study of the
`Liver, March 30—Apri13, 2011, Berlin, Germany, 3 pages.
`2 Suzuki, et ai., “Sustained virological response in a patient with chronic hepatitis C treated by
`monotherapy with the NS3~4A protease inhibitor telaprevir’, Journal of Clinical Virology, 2010. Vol. 47.
`ooaes 76—78.
`
`
`
`
`Examiner
`
`
`
`_
`f
`.
`Date
`12h 4/201 0
`Considered
`./Zenab Olabcwals/
`
`Signature i
`"EXAMiNER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
`considered. Include copy of this form with next communication to applicant. 1 Applicant's unique Citation designation number (optional). 2 See Kinds Codes of
`USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For
`Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by
`the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language
`Translation is attached.
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, This collection is estimated to take 2 hours to complete, including
`gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount
`of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark
`Office. PO. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THlS ADDRESS. SEND To: Commissioner for Patents,
`P.O. Box 1450, Alexandria, VA 22313-1450.
`
`
`
`If you need assistance in completing the form, call 1—800-P/ 0—9199 (7 9800- HIS-9199) and select option 2.
`
`ALL REFEREE iCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/Z.O,/'
`
`

`

`
`
`
`
`
`
`
`
`PTO/SB/OB (0906)
`3/31/2007. OMB 0651-0031
`Approved for use through 0
`US. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`OMB control number.
`Substitute for form 1449/F’TO
`
`Page 3
`
`INFORMATION DISCLOSURE
`
`(use as many sheets as necessary)
`
`Complete if Known
`
`A lication Number
`l 13/875,252
`05—01-2013
`Filing Date
`
`First Named Inventor
`Adrian 5. Ray
`1629
`Art Unit
`Examiner Name
`OLABOWALE, ZENAB O
`
`STATEMENT BY APPLICANT Date Submitted: July 28, 2015
`
`
`
`U.S. PATENT DOCUMENTS
`
`
`
`Pages, Columns, Lines,
`,
`.
`.
`,
`l
`Exami
`Document Number
`I
`net
`i
`Cite
`:
`Publication Date
`Name of Patentee or Applicant of
`Where Relevant
`Initials
`N0,1
`Number-Kind Code2 (if
`i
`MM-DD—YYYY
`Cited Document
`Passages or Relevant
`
`‘
`‘
`known)
`.
`t
`Figures Appear
`
`W WW1,,,,,,,,,,,,,,afliéflégifiw........................L1 103-2012................-
`Wagner 9t 3'-
`
`
`UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS
`
`
`Pages, Columns, Lines,
`.
`Filing Date 01
`US. Patent Application
`t
`.
`Exami
`"91’.
`Cite
`l
`'
`Document
`Cited Document
`Name of Patentee or Applicant of
`Where Relevant
`initials
`No.
`Serial Number-Kind Code2
`MM-DD-YYYY
`Cited Document
`Passages or Relevant
`
`
`(ii known)
`L
`j
`Figures Appear
`
`
`FOREIGN PATENT DOCUMENTS
`
`;
`
`Pages, Columns, Lines,
`l
`.
`Exami
`ner
`Cite MM.) Publication Date
`Name of Patentee or
`Where Relevant
`initials
`No,1
`Country Code ‘Number'
`MM—DD‘YYYY
`Applicant of Cited Documents
`Passages or Relevant
`
`”
`L
`;
`Kind Code5 (if known)
`Figures Appear
`T6
`WO-1996/029336
`
`O9-26«1996
`
`i
`
`Medical Research Council;
`Univeristy College Cardiff
`Consultants Ltd; REGA
`
`
`
`
`I
`Foundation
`3
`l.,,.YY.9;2.9§11.[99Z9_55..................... i....92:93:229§lWWW.............W...N£w919£i.£§lfl,&................................................................. c .
`WO-2005/012327
`l, 02-10-2005
`Univeristy College Cardiff
`l
`......................................................................laWW__ grenadine... _WW_
`WO-2006/121820
`11-16-2006
`Valeant Research &
`W W . - WWW _EWWW-....,_.,WWW_____-__WEW_WW...,...___.,_.WW___Easement....................................................................a
`
`
`NON PATENT LITERATURE DOCUMENTS
`l
`l
`:f”“
`one
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`l
`
`Inmab
`No.‘
`item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue
`E 1"
`
`
`number(s), publisher, city and/or country where published.
`1
`BALZARINI, et al., ”Mechanism of anti~HlV action of masked alaninyl d4’t-MP derivatives" PNAS, (1996), 93:7295—Ali
`l
`7299.
`‘
`l
`CAHARD, et at, ”Aryloxy Phosphoramidato Triostors as Pro~Tidcs,” Mini—Reviews in Medicinal Chomisty, (2004),
`l
`
`W .EEEEL-_W_____.WW .......
`W
`
`CLARK, "Design, Synthesis,
`d Antiviral A
`
`Hepatitis C VirusRepiication," Journal ofMedicinai Chemistry, (2005), 48(17): 5504—5508”
`
`i
`
`.lW ,
`l
`
`._____
`
`I
`
`Examiner
`
`Date
`Considered
`
`12/‘I 4/201 5
`i’Zenab Olabowalet’
`Signature
`”EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
`conSidered. Include copy oi this form with next communication to applicant. 1 Applicants unique citation designation number (optional). 2 See Kinds Codes oi USPTO
`Patent Documents at wwwusptogov or MPEP 901 04. 3 Enter Otfice that issued the document. by the two»|etter code (WlPO Standard ST.3). 4 For Japanese patent
`documents. the indication of the year oi the reign of the Emperor must precede the serial number oi the patent document. 5 Kind oi document by the appropriate
`symbols as indicated on the document under WIPO Standard ST.15 it possible. 6 Applicant is to place a check mark here it English language Translation is attached
`This collection ot information is required by 37 CPR 1 97 and 1,98. The inlormation is required to obtain or retain a benefit by the public which is to tile (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 This collection is estimated to take 2 hours to complete, including
`gathering. preparing, and submitting the completed application loirn to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of
`time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chiei lniormation Otticer, US. Patent and Trademark Oitice.
`PO. Box 1450. Alexandria, VA 223134450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O.
`Box 1450, Alexandria, VA 223134450.
`
`4822-1296-2578.1
`
`If you need assistance in completing the form, call 1 ~800-P 10-9199 (1-800~786«9199) and select option 2.
`
`ALL REFERENCES GONSlDERED EXCEPT WHERE LINED THROUGH.
`
`/Z.O./’
`
`

`

`PTO/SB/08 (09-06)
`Page 4
`Approved for use through 03/31/2007. OMB 06510031
`US, Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`OMB control number.
`
`Substitute for form 1449/PTO
`INFORMATION DISCLOSURE
`
`STATEMENT BY APPLICANT
`Date Submitted: July 28, 2015
`
`
`Complete if Known
`
`13/875,252
`iication Number
`
`05-01-2013
`Filing Date
`
`First Named Inventor
`Adrian 5. Ray
`
`Art Unit
`1629
`
`
`
`(use as many sheets as necessary)
`
`Examiner Name
`
`OLABOWALE, ZENAB O
`37iD-l97097-US
`
`
`
`NON PATENT LITERATURE DOCUMENTS I
`
`Include name of the author (in CAPITAL LETTERS). title of the article (when appropriate). title of the
`Cite
`if“ I
`
`
`
`
`N01 item (book, magazine. journal, serial, symposium. catalog. etc.) date. page(s). volume-issuejInitials T6
`.
`I
`'
`number(s), publisher, city and/or country where published.
`.
`AAAAAAAAA
`DEFRANCESCO, ct al,, "New therapies on the horizon for hepatitis C: are we close?", Ciin Liver Dis, (2003), 7:211—
`242.
`
`s potent hepatitis
`GUNiC, "6- Hydrazinopurine 2‘--methyi ribonucieosides and their 5'monophosphate prodrugs
`...§,...VJIII§.ID.hIeJ.tDISfiesta& Med Chem Letters (2927)171W 2456 2453;._...__-..m_w_.._-_-m......................,......:
`YER, et ai. "Synthesis, in Vitro Anti- Breast Cancer Activity, and Intracellular Decomposition of Amino Acid Methyl
`I
`Ester and Aikyi Amide Phosphoramidate Monoesters of 3Azido-3‘--deoxythymidine (AZT) ," Journal of Medicinal
`I
`
`Chemistry, (2000), 43:2266—2274.
`.ONES, ”iViinireview: Nucleotide Prodrugs," Antiviral Research, (1995), 27:11—17.
`
`
`
`
`
`
`
`
`lM, et ai., ”Direct Measurement of Nucleoside Monophosphate Delivery from a Phosphoramidate
`
`Pronucieotide by Stable isotope Labeling and LC~,ESI-—MS/MS" Molecular Pharmaceutics, (2004), l (2): 102—111.
`-EE et al,, "Selective intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus reverse
`Transcriptase inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue,"
`I
`Antimicrobial Agents and Chemotherapy, (2005), 49(9): 1898~1906_.
`I
`VIA, “Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside inhibitor B—D2'Deoxy--2 Fiuro-
`.
`‘
`i
`2' —-C-Methyicytidine (PSi- 6130) and identification ofa Novel Active 5‘ ~Triphosphate Species," Theiournai of
`
`Biological Chemistry, (2007), 282(41): 29812-29820.
`I
`l
`ViA, et al,, ”Characterization of the intracellular Metabolism of B-d—2’—Deoxy~2’—Fluoro-2’—C—Methyi-Cytidine and
`the inhibition of HCV Polymerase NSSB by its 5’—Triphosphate Species,” Antiviral Research, (2007), 74(3): A36;
`
`
`
`
`
`
`
`f
`I
`
`I
`
`VicGUiGAN, et al., ”Sub Micromolar inhibitors of HCV Generated from inactive Nucleosides by Application of
`£191,i933.sited,es.y;"_Ar:tI:/La_lfie_ssarch (2007) 7413>= A362 Abstract 24.-........................................................................
`VicGUiGAN, "Phosphoramidate derivatives of d4T as inhibitors of HIV: The effect of amino acid variation,"
`Antiviral Research, (1997), 35(3): 95- 204.
`VicGUiGAN, et ai ”Aryi Phosphoramidate Derivatives of d4'i' Have Improved Anti- HiV Efficacy'In Tissue Culture
`and May Act by the Generation of a Novel Intracellular Metabolite,” Journal of Medicinal Chemistry, (1996),
`39: 1748-1753.
`
`)
`
`
`
`
`MCGUIGAN, et ai " Application of Phosphoramidate Pro Tide Technology Significantly improves Antiviral Potency
`of Carbocyclic Adenosine Derivatives“ Journal of Medicinal Chemistry, (2006), 49:7215 7726.
`McGUiGAN, et al,, "Certain Phosphoramidate Derivatives of Dideoxy Uridine (ddU) Are Active Against HiV and
`Successfully By—pass Thymidine Kinase," FEBS Letters, (1994), 351:11—14.
`MURAKAMI, et al., “The Mechanism of Action of beta-D—Z‘~Deoxy-2’-Fiuoro-2'-C-Methylcytidine involves a
`Second Metabolic Pathway Leading to beta~D-2'-Deoxy—Z"Fiuoro~2'nC-Methyiurldine S'-Triphosphate, a Potent
`inhibitor of the Hepatitis C Virus RNA—Dependent RNA Polymerase," Antimicrobial Agents and Chemotherapy,
`
`(2008), 52(2):458-464.
`
`I
`
`I‘Zenab Oiabowaie/
`
`
`
`,,
`Date
`Examiner
`l2/i4/I30i5
`Considered
`Signature
`‘EXAMINER‘ Initial it reference considered, whether or not citation is in conformance with MP EP 609. Draw tine through citation If not in conformance and not
`cons=derod include copy ol this iorm with next communication to applicant. 1 Applicant‘s unique citation designation number (optional). 2 See Kinds Codes oi USPTO
`Patent Documents at www.usplo.gov or MPEP 901,04. 3 Enter Oliice that issued the document, by the two~ietter code (WiPO Standard ST.3). 4 For Japanese patent
`documents. the indication of the year 01 the reign oi the Emperor must precede the serial number of the patent document. 5 Kind oi document by the appropriate
`symbols as indIcated on the document under WiPO Standard ST.16 ii possible. 6 Applicant is to place a check mark here it English language Translation is attached.
`This collection oi information is required by 37 CFR 1 97 and 1.98. The iniormation is required to obtain or retain a beneiit ‘oythe public which is to tile (and by the
`USPTO to process) an application. ConfidentIaiity is governed by 35 use. 122 and 37 CFR 1.14 This collection is estimated to take 2 hours to compie1e. including
`gathering. preparing, and submittmg the completed application iorm to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of
`time you require to complete this form and/or suggestions for reducing this burden. should be sent to the Chief Information Officer, US. Patent and Trademark Office,
`PO. Box 1450. Alexandria, VA 22313 1450. DO NOT SEND FEES OR COMPLETED FORMS TO Tl—ilS ADDRESS. SEND TO: Commissioner for Patents, P.O.
`Box 1450, Alexandria, VA 22313-1450.
`
`.
`
`4822429625781
`
`It you need aSSIstance in completing the form, call 1-800—P i 09199 {1-800—786—9799} and select option 2.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`I'Z.O./’
`
`

`

`PTO/SB/OS (0906)
`Approved for use through 03/31/2007. OMB 0651 -0031
`US, Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`OMB control number.
`
`Page 5
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`Date Submitted: July 28, 2015
`
`
`Complete if Known
`
`Application Number
`13/875,252
`Filing Date
`Adrian S. Ray
`First Named inventor
`
`Art Unit
`1629
`
`(use as many sheets as necessary)
`
`Examiner Name
`
`OLABOWALE, ZENAB O
`
`heet
`
`05-01-2013
`
`
`
`
`
`NON PATENT LITERATURE DOCUMENTS i
`if?“
`one
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`i
`1
`Walls
`No.1
`item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue
`i T6
`
`___
`number(s). publisher, city and/or country where published.
`_
`MURAKAMI, at at, "The Mechanism of Action of BeD—2'~Dcoxy-2'-FIuoro—2'-C-Methylcytidine Inhibition of
`L. WWW we. «2.2, i___e___.____Ww....__.__._._._..____.-A.-_..._w-flm-
`Hepatitis C Virus NSSB RNA Polymerase," Antimicrobial Agents and Chemotherapy, (3007), 52(2)ng8 £164.
`PERRON E, et at ”First Example of Phosphoramidate Approach Applied to a 4’ Substituted Purine Nucleoside (4’—
`Azidoadenosine): Conversion of an Inactive Nucleoside to a Submicromolar Compound versus Hepatitis C Virus”
`Journal of Medicinal Chemistry, (2007), 50:5463-5470.
`SABOULARD, et aI. "Characterization of the Activation Pathway of Phosphoramidate Triester Prodrugs of
`Stavudine and Zidovudine" American Society for Pharmacology and Experimental Therapeutics, (1999), 56, 693-
`704
`I
`SOFIA, et al., "B-D-2’-Deoxy-2;fiuro-2’-C-methyluridine Phosphoramidates: Potent and Selective Inhibitors of HCV E
`RNA Replication,” (Sept. 2007), Poster P—259, 1 page.
`'
`i
`
`
`
`3
`i
`‘
`
`
`
`Date
`
`Examiner
`12/14/2015
`Considered
`i’Zenab Olabowale/
`Signature
`‘EXAMINER' Initial if reference considered. whether or not citation is in conformance with MPEP 609, Draw iine through citation if not in conformance and not
`considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation destgnation number (optional). 2 See Kinds Codes oi USPTO
`Patent Documents at www.uspto.gov or MP EP 901 ,04. 3 Enter Oiiice that issued the document. by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent
`documents. the indication of the year oi the reign oi the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate
`symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.
`This collection 01 information is required by 87 CFR 1 07 and 1.98, The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 This collection is estimated to take 2 hours to complete, including
`gathering. preparing, and submitting the completed application term to the USPTO. Time will vary depending upon the individual case. Any comments on the amount oi
`time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, US. Patent and Trademark Office.
`PO. Box 1450. Alexandria, VA 223131450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, PO.
`Box 1450, Alexandria, VA 2231 3.1450,
`
`4822-1 29625781
`
`If you need aSSIS lance in completing the form, call 1-800-P'1'O-9199 ( 7-800— 786-9199) and select option 2,
`
`ALL REFERENCES CONSiDEREQ EXCEPT WHERE LlNED THROUGH. (2.01
`
`

`

`Page 6
`
`PTO/SB/OS (0906)
`Approved for use through 03/81/2007. OMB 0651 0031
`US. Patent and Trademark Office: US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`OMB control number.
`
`Substitute for form 1449/PTO
`Complete if Known
`13/875252
`A- lication Number
`05-01-2013
`FilingDate
`Adrian S. Ray
`First Named inventor
`Date Submitted: July 1, 2015
`1629
`Art Unit
`Examiner Name
`OLABOWALE, ZENAB O
`(use as many sheets as necessary)
`Attorne Docket Number
`
`U.S. PATENT DOCUMENTS
`
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`.
`Pages, Columns, Lines,
`3
`.
`Document Number
`3
`Exam;
`
`Name of Patentee or Applicant of
`Where Relevant
`Publication Date
`Cite
`ner
`initials
`No.1
`Number-Kind Code2 (if
`MM-DD-YYYY
`Cited Document
`Passages or Relevant
`
`‘
`i
`know")
`3
`Figures Appear
`
`3 A1
`l 05-2001/0034440
`i
`10-25-2001
`SHEPARD ET AL.
`
`3
`A2
`3 L$»2001/0038833
`1
`11-08-2001
`RYBACK ET AL.
`
`A3
`3 LS~2002/0008241
`01-24-2002
`EDMOND ET AL.
`
`A4
`LS-2002/0058635
`;
`05-1e2002
`AVERETT
`
`A5
`L 52002 /0147160
`‘
`10-102002
`BHAT ET AL.
`
`A6
`‘5 US-2002/0198173
`3
`12-26—2002
`SCHiNAZl ET AL.
`
`3
`A7
`: L 5—2003/0050229
`1
`03-13-2003
`SOMMADOSS] ET AL.
`
`A8
`'
`s2003/0060400
`3
`03-27-2003 3 LAcoLLA ETAL.
`
`A9
`Ls2003/0109697
`07.122003
`SHEPARD ET AL,
`
`A10
`. LS<2003/0119752
`06‘26—2006
`FARMER ET AL.
`A11
`05-2003/0144502
`1
`074312003
`PIETRZKOWSKI ET AL.
`
`3 A12
`LS~2003/0153744
`41
`08-14~2003
`MEKOUAR ET AL.
`
`A13
`US—2003/0176433
`3
`09—18-2003
`BEAULlEU ET AL.
`3 A14
`. LS~2003I0187018
`%
`10—02—2003
`LLiNAS-BRUN ET ET AL.
`A15
`3 05—2003/0207922
`‘3
`11-0e2003
`NEUNER ET AL.
`
`A16
`US-2004/0006007
`3
`01-08-20047 GOSSELIN ET AL.
`
`A17
`LS~2004/0014108
`01-222004 3 ELDRUP ET AL.
`
`A18
`L 52004/0023901
`3
`0205—2004
`COOK ET AL
`
`A19
`1
`5—2004/0024190
`02-052004
`BEAULiEU ET AL.
`
`A20
`3 05.2004/0059104
`[
`03-25—2004 3 COOK ET AL.
`
`A21
`US-2004/0063622
`3
`04-01-2004
`SOMMADOSSl ET AL.
`3 A22
`3 Ls2004/ooe7901
`04082004
`BHAT ET AL.
`
`A23
`Ls-2004/0072788
`0415-2004
`BHAT ET AL.
`
`3
`A24
`‘3 US-2004/0087541
`3
`05—0e2004
`JONAlTiS ET AL.
`
`A25
`US-2004/0097461
`i
`05-202004
`SOMMADOSSI ET AL.
`
`A26
`3 US-2004/0097462
`05-202004
`SOMMADOSSI ET AL.
`
`A27
`05-2004/0101535
`05-27-2004
`SOMMADOSS] ET AL.
`
`A28
`3 05-2004/0102414
`05.27-2004
`somtvmoossr ET AL.
`
`A79
`05.2004/0110717
`3
`06-10-7004
`CARROH FT AL.
`
`A30
`05-2004/0142989
`3
`07-22-2004
`FlNZELET AL.
`
`3
`; A31
`us2004/0142993
`3
`07222012
`BATTISTlNi ET AL.
`
`A32
`3 US-ZOQfl/0167140M
`3
`08-26—2004
`SCHINAZi ET AL.
`
`3 A33
`3 05-2004/0171570
`l
`09—02—2004
`ALLERSON ET AL.
`
`A34
`us2004/0214844
`10~28~2004
`OTTO ET AL.
`
`A35
`US—2004/0229839
`3
`11-18-2004
`BABU ET AL.
`‘ A36
`3 05200400229840
`i
`1148-2004
`BHAT ET AL.
`
`A37
`05-2004/0254141
`i
`12-102004
`SCHlNAZi ET AL.
`
`37lD-197097-US
`
`
`
`
`
`
`
`
`Examiner
`
`i
`
`/Zenab Oiabowaie/
`
`Signature
`’EXAMINER' Initial ii reference considered. whether or not citation is in conformance with MP EP 609, Draw iine through citation if no
`conszdered. include copy oi this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO
`Patent Documents at wwwusptogov or MP EP 901 O4. 3 Enter Oitice that issued the document. by the two-letter code (WlPO Standard ST.3). 4 For Japanese patent
`ocument by the appropriate
`documents. the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of c
`anguage Translation is attached.
`symbols as indicated on the document under WIPO- Standard 81716 it possible. 6 Applicant is to place a check mark here if English
`This collection of information is required by 37 CFR 1 07 and 1.98. The tnlormation is required to obtain or retain a benefit by the public which is to file (and by the
`USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14 This collection 15 estimated to take 2 hours to complete. including
`gathering. preparing. and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of
`time you require to complete this form and/or suggestions for reducing this burden. should be sent to the Chief Information Officer, US. Patent and Trademark Office.
`PO. Box 1450. Alexandria. VA 22313 1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO.
`Box 1450, Alexandria, VA 22313-1450.
`
`Date
`Considered
`
`12/14/2015
`i in conformance and not
`
`
`
`SMRH 14390729921
`
`If you need assrstance in completing the form, call 7600-,“ 'I"()~9199 (1-800— 7869199) and select Option 2.
`
`ALL REFERENCES CONSiDERED EXCEPT WHERE LlNED THROUGH.
`
`i‘Z.O./
`
`

`

`PTO/SB/O8 (09-06)
`Approved for use through 03/31/2007. OMB 0651-0031
`US. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
` OMB control number.
`Substitute for form t449/PTO
`Complete if Known
`
`A oiication Number
`i 13/875252
`05—01-2013
`Fi
`Egg Date
`
`First Named Inventor
`Adrian 8. Ray
`1629
`Art Unit
`
`Examiner Name
`| OLABOWALE, ZENAB O
`37JD-197097-US
`
`INFORMATION DiSCLOSURE
`STATEMENT BY APPLICANT
`
`Date Submitted: July 1, 2015
`
`Page 7
`
`Attorne Docket Number
`
`(use as many sheets as necessary)
`
`.
`
`BRAVI ET AL.
`02-24-2005
`COLONNO ET AL.
`03-31-2005
`STORER ET AL.
`04-07-2005
`STANDRING ET AL.
`04-14-2005
`04—21-2005 MAUPlN ET AL.
`04-28-2008 MCPHEE ET AL.
`05-05-2005
`ROMINE ET AL.
`05-12-2005
`HATHAWAY ET AL.
`06-09-2005
`somrvmoossr ET AL.
`06—16—2005
`
`L
`
`,
`E
`
`;
`
`.
`
`
`U.S. PATENT DOCUMENTS
`
`Exami
`Cite
`Document Number
`E
`Publication Date
`Name of Patentee or Applicant of
`Pages, Columns, Lines,
`ner
`i
`[5 o 1
`i
`3
`MAIL-DD-YYYV
`t med [Mani—AWL».—
`V
`
`E US-2004/0259934
`12-23—2004
`OLSEN ET AL.
`
`US-2005/0031588 02-10-2005 WWSOMMADASSI ET AL.
`
`E US—7004/0765969
`17-30-7004
`[I FT AL
`
`
`E US-2005/0026160
`02—03—2005
`ALLERSON ET AL.
`
`US~2005/0026853 02-03—2005 E MEKOUAR ET AL.
`
`
`
`.
`‘ U$-~2005/0043390
`
`A44 E US—2005/0069522
`1 A45
`E 05-2005/0075309
`i A46
`05-2005/0080034
`A47
`US—ZOOS/OO82144
`‘
`4 A48
`05-2005/0090432
`l
`A49
`E US»2005/0096364
`E
`A50
`E US-2005/0098125
`E
`i A51
`05-2005/0124532
`.
`A52
`05-2005/0130923
`OG-leOLi
`
`
`E
`' us2005/0130931
`' A5}
`06-23-2005
` US»2005/0137161
`
`CASTELLiNO ET AL.
`05-2005/0148534
`1 A55
`07-07-2005
`
`
`E A56
`us-2005/0154056
`07-14-2005 . YANG ET AL
`
`A57
`US~2005/0164960
`07-28-2005
`OLSEN ET AL.
`A58
`. 05-2005/0215513
`09-29-2005
`BOOJAMRA ET AL.
`A59
`; US—2005/0215614
`09-29-2005
`SlNGH ET AL.
`1; A60
`us-2005/0227947
`10-13-2005
`CHEN ET AL.
`k
`A6]
`US-2005/0228013
`E
`10-13-2005
`THURKAUF ET AL.
`
`US-2005/0261237
`E
`11-24-2005
`BOOJAMRA ET AL.
`7
`
`i US-2006/0003951
`01-05-2006 MEKOUAR ET AL.
`
`E.........01‘Q§:.%906 ._Fl'\£§L§I_/5L
`-.................................. _ a
`U5.:_2,C£3.6_/£099_0§§.....................
`
`us-2006/0035866
`02-16-2006
`CANNIZZARO ET AL.
`2
`
`
`
`
`
`
`
`
`..
`
`a, _ _ -
`
`.2
`
`us-2006/0040890
`i
`02-23-2006
`MARTlN ET AL.
`
`05-2006/0040927
`E
`02-23-2006
`BLAKE ET AL.
`
`E US-2006/0040944
`02-23—2006
`GOSSELlN ET AL.
`
`US—2006/0046983
`3
`03-02-2006
`HUDYMA ET AL.
`
`US—2006/OO79478
`E
`04-13-2006
`BOOJAMRA ET AL.
`
`U5-2006/0094706
`05-04-2006
`PARUCH ET AL.
`
`E us-2006/0110724
`05—25—2006
`BURKHARDT ET AL.
`.
`
`i US-2006/0122154
`i
`06—08-2006
`OLSEN ET AL.
`L
`E US—2006/0194749
`E
`08-31—2006
`KEiCHER ET AL.
`05-2006/0166964
`E
`07-27-2006
`HUDYMA
`
`US-2006/0234962
`E
`10-19-2006
`OLSEN ET AL.
`
`Examiner
`
`i’Zenab Oiebowaie/
`
`12/14/20i5
`
`Signature i
`'EXAMiNER: initial it reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not
`considered. include copy oi this form with next communication to applicant. t Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO
`Patent Documents at www.uspto.gov or MP EP 9m .04. 3 Enter Oitice that issued the document, by the two-letter code (WlPO Standard ST.3). 4 For Japanese patent
`ocument by the appropriate
`documents, the indication oi the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind cl c
`anguage Translation is attached,
`symbols as indicated on the document under WiPO Standard ST 16 it possible. 6 Applicant is to place a check mark here it English
`This collection of information is required by 37 CFR 1 97 and 1.98. The iniormation is required to obtain or retain a benefit by the public which is to tile (and by the
`USPTO to process) an application. Contidentiality is governed by 35 USO. 122 and 37 CFR t.t4. This collection is estimated to take 2 hours to complete. including
`gathering. preparing. and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount Oi
`time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office.
`PO. Box 1450. Alexandria, VA 22313 1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO.
`Box 1450, Alexandria, VA 22313—1450.
`
`Date
`Considered
`
`SMRH 24390729921
`